Non-valvular atrial fibrillation accounts for 13–26% of acute ischaemic strokes.1 Direct oral anticoagulants (DOACs) are ...

The revenue increases came from across BMS’s portfolio, including legacy products like Eliquis and Revlimid and growth products like Opdivo, Yervoy and Reblozyl. The company expects 2025 revenue to be ...

Reversibility in Bleeding Patients The phase II feasibility study included 30 patients (93% male) implanted with the HeartMate 3 (Abbott Cardiovascular) who were randomized to apixaban 5 mg or ...

Interpretation: The results of this trial indicate that among patients with an On-X mechanical aortic valve implanted ≥3 months earlier, apixaban 5 mg BID did not meet criteria for noninferiority ...

The warfarin group had an INR time within the time-in-therapeutic range of 73%. Apixaban was noninferior to warfarin for LVT resolution, with no statistical difference occurring in resolution rates.

Dharam J. Kumbhani, MD, SM, FACCStudy Design Patients were randomized in a 1:1 fashion to an oral anticoagulant with either apixaban 2.5 mg BID (n = 48) or phenprocoumon international normalized ratio ...

Pokorney et al 6 in this issue of Circulation report the results of the randomized, open-label, blinded–end point RENAL-AF trial (Renal Hemodialysis Patients Allocated Apixaban Versus Warfarin in ...

CPD: Key questions on anticoagulation Editorial use only MODEL RELEASED. Apixaban anticoagulant drug. Patient taking a tablet of the anticoagulant drug apixaban (marketed as Eliquis). This drug is ...